Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 13;3(3):e000344.
doi: 10.1136/esmoopen-2018-000344. eCollection 2018.

Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?

Joseph A Pinto  1 , Carlos S Vallejos  2 , Luis E Raez  3 , Luis A Mas  2 , Rossana Ruiz  2 , Junior S Torres-Roman  4 , Zaida Morante  2 , Jhajaira M Araujo  1 , Henry L Gómez  2 , Alfredo Aguilar  2 , Denisse Bretel  5 , Claudio J Flores  1 , Christian Rolfo  6
Affiliations

Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?

Joseph A Pinto et al. ESMO Open. .

Abstract

Background: There are well-known differences in gender outcome in non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the gender influence in the outcome of patients with NSCLC treated with targeted therapy and immunotherapy.

Methods: We performed a series of meta-analysis to compare the gender outcome in the routine setting for overall survival and progression-free survival (PFS) in phase III randomised clinical trials comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, LUX-lung 6, EURTAC, ENSURE and WTJOG); ALK inhibitors versus chemotherapy (ASCEND 4, ASCEND 5, PROFILE 1014 and NCT009323893) and anti-PD1 checkpoint inhibitors versus chemotherapy (CheckMate 017, CheckMate 026, CheckMate 057, KEYNOTE 010 and KEYNOTE 024).

Results: Female patients with NSCLC have a reduced risk of death compared with men (HR=0.73; 95% CI 0.67 to 0.79; p<0.00001). Women had a better benefit from EGFR inhibitors than men (HR=0.34; 95% CI 0.28 to 0.40; p<0.00001 vs HR=0.44; 95% CI 0.34 to 0.56; p<0.00001, respectively). The benefit from ALK inhibitors was similar for both genders (HR=0.51; 95% CI 0.42 to 0.61; p<0.00001 vs HR=0.48; 95% CI 0.39 to 0.59; p<0.00001, for women and men, respectively). Anti-PD1 inhibitors significantly improved the PFS in male patients when compared with chemotherapy (HR=0.76; 95% CI 0.68 to 0.86; p<0.00001); in contrast, women showed no benefit in 5/5 randomised trials (HR=1.03; 95% CI 0.89 to 1.20; p=0.69).

Conclusions: In this exploratory study, some targeted treatments were influenced by gender. Despite differences in outcomes that could be attributed to different histology, EGFR and smoking status, gender should be evaluated more deeply as prognostic variable in patients with NSCLC.

Keywords: gender; non-small cell lung cancer; prognostic factors; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Results show that gender is a prognostic factor favouring female patients (A). The funnel plot shows no publication bias among studies included in the analysis (B).
Figure 2
Figure 2
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung cancer (NSCLC) have a minor benefit from these drugs (A) compared with female patients who have a 10% additional reduction in progression risk (B). Funnel plots for the detection of publication bias in the meta-analysis of men (C) and women (D).
Figure 3
Figure 3
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients (A) and female patients (B). There was no observed publication bias in the analysis of men (C) or women (D).
Figure 4
Figure 4
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Women have a decreased benefit from anti-PD1 inhibitors nivolumab and pembrolizumab (B). Funnel plots showing publication bias in meta-analysis of male (C) or female patients (D).
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. . Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. (accessed 8 Aug 2017).
    1. Egleston BL, Meireles SI, Flieder DB, et al. . Population-based trends in lung cancer incidence in women. Semin Oncol 2009;36:506–15. 10.1053/j.seminoncol.2009.09.003 - DOI - PMC - PubMed
    1. Risch HA, Howe GR, Jain M, et al. . Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993;138:281–93. - PubMed
    1. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88:183–92. 10.1093/jnci/88.3-4.183 - DOI - PubMed
    1. de Perrot M, Licker M, Bouchardy C, et al. . Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000;119:21–6. 10.1016/S0022-5223(00)70213-3 - DOI - PubMed